Ocular Drug Delivery for Glaucoma Management

Pharmaceutics

Nathan Gooch³  Sarah A. Molokhia¹  Russell Condie³  Randon Michael Burr²  Bonnie Archer²  Balamurali K. Ambati² 

[1] Department of Pharmacy, University of Utah, Salt Lake City, UT, USA;Moran Eye Center, University of Utah, Salt Lake City, UT, USA;Department of Bioengineering, University of Utah, Salt Lake City, UT, USA

关键词: glaucoma;    IOP;    drug delivery;    sustained release;    polymer;    inserts;    punctal plug;   

DOI  :  10.3390/pharmaceutics4010197

来源: mdpi

【 摘 要 】

Current glaucoma management modalities are hindered by low patient compliance and adherence. This can be due to highly complex treatment strategies or poor patient understanding. Treatments focus on the management or reduction of intraocular pressure. This is most commonly done through the use of daily topical eye drops. Unfortunately, despite effective therapies, glaucoma continues to progress, possibly due to patients not adhering to their treatments. In order to mitigate these patient compliance issues, many sustained release treatments are being researched and are entering the clinic. Conjunctival, subconjunctival, and intravitreal inserts, punctal plugs, and drug depots are currently in clinical development. Each delivery system has hurdles, yet shows promise and could potentially mitigate the current problems associated with poor patient compliance.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.